PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 21, 2013Journal of Clinical Oncology1,315 citationsOpen Access

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

KHKevin S. HughesLSLauren A. SchnaperJBJennifer R. Bellon

Key Points

  • Evaluate the long-term impact of adding radiation therapy to lumpectomy and tamoxifen on recurrence and survival outcomes in women aged 70 years or older with early-stage, estrogen receptor-positive breast cancer.
  • Long-term follow-up evaluation of the CALGB 9343 trial in women aged 70 years or older with estrogen receptor-positive early breast cancer.
  • Assessed outcomes among patients receiving lumpectomy plus tamoxifen with or without adjuvant radiation therapy, focusing on locoregional recurrence, distant disease-free survival, breast preservation, and overall survival.
  • Adjuvant radiation therapy maintained a persistent, modest reduction in locoregional recurrence compared to tamoxifen alone.
  • The addition of radiation therapy showed no advantage in overall survival, distant disease-free survival, or rates of breast preservation.

Abstract

With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hughes et al. (2013) studied this question.

synapsesocial.com/papers/69d8990dde3177251abedabbhttps://doi.org/10.1200/jco.2012.45.2615
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.1997 · 94 citations
  2. 2Tamoxifen for breast cancer prevention among survivors of pediatric lymphoma previously treated with chest radiation: Clinical benefits, harms and tradeoffs.2024 · 1 citations
  3. 3Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up2026
  4. 4Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and older2026
  5. 5Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up2024 · 4 citations